KRTL Holding Group Expands in Bolivia: A Strategic Leap for Biopharmaceutical Innovation
KRTL Holding Group (OTC: KRTL) has announced a strategic expansion in Bolivia through a joint venture between its subsidiaries, KRTL Biotech and KRTL International, and Centro de Investigaciones Químicas (CIQ). Each subsidiary secured a 9.99% stake in 3451.5 acres of land in the Amazon region, totaling 689.9 acres.
The partnership aims to establish sustainable API extraction, research, and manufacturing facilities in Bolivia, with three key facilities planned in Quillacollo, Santa Cruz, and Cochabamba. CIQ, led by Dr. Bascope, specializes in extracting high-value botanical ingredients from Bolivia's diverse ecosystems.
Through this venture, KRTL Biotech will introduce CIQ's products, including cosmetics, raw materials, minerals, and APIs, to the U.S. market following FDA registration requirements. The collaboration also provides access to CIQ's exotic molecule library for potential pharmaceutical applications in pain management, anti-inflammatory treatments, and dermatology.
KRTL Holding Group (OTC: KRTL) ha annunciato un'espansione strategica in Bolivia attraverso una joint venture tra le sue filiali, KRTL Biotech e KRTL International, e il Centro de Investigaciones Químicas (CIQ). Ciascuna filiale ha acquisito una partecipazione del 9,99% in 3451,5 acri di terreno nella regione amazzonica, per un totale di 689,9 acri.
La partnership mira a stabilire strutture sostenibili per l'estrazione, la ricerca e la produzione di API in Bolivia, con tre impianti chiave previsti a Quillacollo, Santa Cruz e Cochabamba. CIQ, guidato dal Dott. Bascope, è specializzato nell'estrazione di ingredienti botanici di alto valore dagli ecosistemi diversificati della Bolivia.
Attraverso questa venture, KRTL Biotech introdurrà i prodotti di CIQ, tra cui cosmetici, materie prime, minerali e API, nel mercato statunitense seguendo i requisiti di registrazione della FDA. La collaborazione offre anche accesso alla libreria di molecole esotiche di CIQ per potenziali applicazioni farmaceutiche nella gestione del dolore, nei trattamenti anti-infiammatori e in dermatologia.
KRTL Holding Group (OTC: KRTL) ha anunciado una expansión estratégica en Bolivia a través de una empresa conjunta entre sus filiales, KRTL Biotech y KRTL International, y el Centro de Investigaciones Químicas (CIQ). Cada filial aseguró una participación del 9,99% en 3451,5 acres de tierra en la región amazónica, sumando un total de 689,9 acres.
La asociación tiene como objetivo establecer instalaciones sostenibles para la extracción de API, investigación y fabricación en Bolivia, con tres instalaciones clave planificadas en Quillacollo, Santa Cruz y Cochabamba. CIQ, dirigido por el Dr. Bascope, se especializa en la extracción de ingredientes botánicos de alto valor de los diversos ecosistemas de Bolivia.
A través de esta empresa, KRTL Biotech introducirá los productos de CIQ, incluidos cosméticos, materias primas, minerales y API, en el mercado estadounidense cumpliendo con los requisitos de registro de la FDA. La colaboración también proporciona acceso a la biblioteca de moléculas exóticas de CIQ para posibles aplicaciones farmacéuticas en el manejo del dolor, tratamientos antiinflamatorios y dermatología.
KRTL 홀딩 그룹 (OTC: KRTL)는 자회사인 KRTL 바이오텍 및 KRTL 인터내셔널과 Centro de Investigaciones Químicas (CIQ) 간의 합작 투자로 볼리비아에서의 전략적 확장을 발표했습니다. 각 자회사는 아마존 지역의 3451.5 에이커의 토지에서 9.99%의 지분을 확보했으며, 총 689.9 에이커에 달합니다.
이번 파트너십의 목표는 볼리비아에서 지속 가능한 API 추출, 연구 및 제조 시설을 설립하는 것으로, Quillacollo, Santa Cruz 및 Cochabamba에 세 개의 주요 시설이 계획되어 있습니다. CIQ는 Bascope 박사의 지도 아래 볼리비아의 다양한 생태계에서 고부가가치 식물 성분을 추출하는 전문 기관입니다.
이 합작 투자로 KRTL 바이오텍은 FDA 등록 요건에 따라 CIQ의 제품, 즉 화장품, 원료, 미네랄 및 API를 미국 시장에 도입할 것입니다. 이 협업은 또한 통증 관리, 항염 치료 및 피부과 분야의 잠재적 제약 응용을 위한 CIQ의 이국적인 분자 라이브러리에 대한 접근을 제공합니다.
KRTL Holding Group (OTC: KRTL) a annoncé une expansion stratégique en Bolivie à travers une coentreprise entre ses filiales, KRTL Biotech et KRTL International, et le Centro de Investigaciones Químicas (CIQ). Chaque filiale a acquis une participation de 9,99% dans 3451,5 acres de terre dans la région amazonienne, totalisant 689,9 acres.
Le partenariat vise à établir des installations durables pour l'extraction, la recherche et la fabrication d'API en Bolivie, avec trois installations clés prévues à Quillacollo, Santa Cruz et Cochabamba. CIQ, dirigé par le Dr. Bascope, est spécialisé dans l'extraction d'ingrédients botaniques de haute valeur provenant des écosystèmes diversifiés de la Bolivie.
Grâce à cette coentreprise, KRTL Biotech introduira les produits de CIQ, y compris des cosmétiques, des matières premières, des minéraux et des API, sur le marché américain en respectant les exigences d'enregistrement de la FDA. La collaboration permet également d'accéder à la bibliothèque de molécules exotiques de CIQ pour de potentielles applications pharmaceutiques dans la gestion de la douleur, les traitements anti-inflammatoires et en dermatologie.
KRTL Holding Group (OTC: KRTL) hat eine strategische Expansion in Bolivien durch ein Joint Venture zwischen ihren Tochtergesellschaften, KRTL Biotech und KRTL International, sowie dem Centro de Investigaciones Químicas (CIQ) angekündigt. Jede Tochtergesellschaft sicherte sich einen Anteil von 9,99 % an 3451,5 Acres Land in der Amazonasregion, insgesamt also 689,9 Acres.
Die Partnerschaft zielt darauf ab, nachhaltige Einrichtungen zur Extraktion, Forschung und Herstellung von APIs in Bolivien zu etablieren, wobei drei zentrale Einrichtungen in Quillacollo, Santa Cruz und Cochabamba geplant sind. CIQ, geleitet von Dr. Bascope, ist auf die Extraktion von hochwerigen botanischen Inhaltsstoffen aus Boliviens vielfältigen Ökosystemen spezialisiert.
Durch dieses Joint Venture wird KRTL Biotech die Produkte von CIQ, einschließlich Kosmetik, Rohstoffen, Mineralien und APIs, gemäß den Anforderungen der FDA auf dem US-Markt einführen. Die Zusammenarbeit ermöglicht zudem den Zugang zur exotischen Molekülbibliothek von CIQ für mögliche pharmazeutische Anwendungen in der Schmerztherapie, bei Entzündungsbehandlungen und in der Dermatologie.
- Strategic acquisition of 19.98% stake in 3451.5 acres of Bolivian land
- Access to CIQ's extensive exotic molecule library for pharmaceutical development
- Planned development of three manufacturing facilities in Bolivia
- Partnership with over 40 international universities for research collaboration
- Potential for market expansion through FDA-compliant product introduction to U.S. market
- Land acquisition still pending government approval
- Products require FDA review and approval before commercialization
- Heavy dependence on regulatory compliance for market entry
Lakewood, CO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC: KRTL) is strategically expanding its presence in the heart of South America, where biodiversity flourishes and untapped resources promise new frontiers in medicine. Recognizing Bolivia’s vast potential, KRTL’s subsidiaries, KRTL Biotech, Inc. and KRTL International Corp., have formed a strategic joint venture with Centro de Investigaciones Químicas - CIQ S.R.L., a leading Bolivian research and manufacturing institution led by the esteemed Dr. Bascope.
A Vision for Sustainable Growth
For decades, the global pharmaceutical supply chain has been dominated by traditional hubs like China and India. However, shifting economic landscapes and growing concerns over sustainability have created an opportunity for diversification. Bolivia, with its rich natural resources and cost-effective production, stands as an emerging leader in the biotech and pharmaceutical sectors.
KRTL’s joint venture with CIQ goes beyond securing a
Bridging Markets: Bolivia to the U.S.
Through this joint venture, KRTL Biotech will introduce CIQ’s real estate holdings, cosmetic products, raw materials, minerals, and active pharmaceutical ingredients (APIs) into the U.S. market through a structured regulatory pathway. By aligning with FDA registration requirements and international pharmaceutical regulations, this partnership ensures seamless distribution and market entry while maintaining strict regulatory compliance. This collaboration paves the way for broader market accessibility and sustainable commercialization of CIQ’s natural-based innovations.
The Role of CIQ in This Strategic Expansion
CIQ is no ordinary research institution. As a hub of pharmaceutical and cosmetic innovation, it specializes in the extraction of high-value botanical ingredients sourced from Bolivia’s diverse ecosystems, including the Amazon rainforest and the Andes Mountains. This partnership enables CIQ to scale its operations beyond Bolivia’s borders, leveraging established trade agreements and documented regulatory pathways to access new international markets.
Dr. Bascope, a renowned scientist and visionary in the field, sees this partnership as an evolution in sustainable pharmaceutical production. “This joint venture expands CIQ’s potential far beyond Bolivia, allowing us to introduce our botanical extracts and APIs to new markets while advancing scientific research through KRTL Biotech’s regulatory expertise,” said Dr. Bascope.
Infrastructure & Sustainable Development
The joint venture will also facilitate the development of three key facilities, two in Quillacollo and Santa Cruz, and a third in Cochabamba in partnership with SIGMA, enhancing Bolivia’s growing role in global biotech manufacturing. KRTL International will oversee infrastructure expansion, including carbon credit initiatives and reforestation projects, while KRTL Biotech manages regulatory compliance, enabling products to meet stringent U.S. and international pharmaceutical standards.
Innovation at the Core: The Future of API Production
Beyond land acquisition, this collaboration secures KRTL Biotech’s access to CIQ’s extensive library of exotic molecules, which are subject to further regulatory review and approval under FDA guidelines before pharmaceutical application, opening doors to pharmaceutical advancements in pain management, anti-inflammatory treatments, and dermatological applications. Moreover, with partnerships spanning over 40 international universities, CIQ provides a foundation for cutting-edge research and innovation in molecular biology and sustainable chemistry, creating further opportunity in the US considering today’s geopolitical landscape.
A Commitment to Sustainable Pharmaceutical Leadership
As global biotech markets seek alternatives to traditional supply chains, KRTL Holding’s expansion into Bolivia presents a forward-thinking approach that benefits both economic and environmental sustainability. With Sigma Corp. as a key manufacturing partner, the venture ensures efficient production and distribution, reinforcing Bolivia’s role as a rising force in pharmaceutical innovation.
Cesar Herrera, CEO of KRTL Holding Group, Inc., emphasizes the significance of this milestone: “KRTL continues to expand strategically, forming key international collaborations to strengthen market access, supply chain control, operational capabilities and enhancing our partnerships, which combined with our FDA registrations, gives us the ability to sell pharmaceutical products from Bolivia in the US.”
Final Thoughts: A Game-Changer in the Making
With this strategic move, KRTL Biotech is not just expanding its footprint—it is redefining the future of pharmaceutical production. By embracing Bolivia’s biodiversity, investing in research, and ensuring compliance with international regulations, KRTL Biotech is paving the way for a sustainable and innovative biotech ecosystem.
As KRTL Holding continues its strategic growth, each press release represents a piece of a larger, evolving journey. These updates highlight key milestones and initiatives, but the full scope of KRTL's vision will become increasingly clear with future announcements. We encourage stakeholders to follow our progress as we integrate innovation, sustainability, and market expansion into a comprehensive strategy for long-term success.
About KRTL Biotech Inc.: KRTL Biotech Inc., a wholly owned subsidiary of KRTL Holding Group Inc., specializes in pharmaceutical registration, regulatory compliance, and FDA services for both international and domestic clients. The company plays a pivotal role in product registration and importation, ensuring seamless integration into the U.S. market. In addition, KRTL Biotech excels in client acquisition, sourcing exclusive APIs, and providing strategic regulatory guidance. Their innovative approach to navigating the complexities of pharmaceutical compliance and market entry positions them as a key driver of success for their partners and clients.
About Centro de Investigaciones Químicas, S.R.L: CIQ S.R.L. is a premier Bolivian research and manufacturing institution specializing in the extraction, refinement, and application of high-value natural compounds. Under the leadership of Dr. Bascope, CIQ collaborates with a global consortium of research institutions, advancing the frontiers of cosmetic science, pharmaceutical innovation, and industrial biochemistry. With a focus on sustainable resource utilization and pioneering research methodologies, CIQ remains a leader in advancing Bolivia’s scientific innovation and commercial applications for bioactive compounds.
About KRTL Holding Group Inc.: KRTL Holding Group Inc. operates through its wholly owned subsidiaries, KRTL Biotech Inc. and KRTL International Corp., focusing on pharmaceutical innovation and compliance. By fostering strategic partnerships and leveraging synergies across its subsidiaries, KRTL Holding Group enhances shareholder value and maintains a competitive edge in the marketplace.
Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
The information contained herein includes forward-looking statements, as defined under the Private Securities Litigation Reform Act of 1995. These statements relate to future events or financial performance and involve risks and uncertainties, including but not limited to market conditions, regulatory approvals, operational challenges, and other factors that could cause actual results to differ materially from those anticipated. KRTL assumes no obligation to publicly update or revise these statements to reflect changes in circumstances or unforeseen events, except as required by law.
FAQ
What is KRTL's recent expansion strategy in Bolivia?
How much land did KRTL acquire in Bolivia through the joint venture?
What are the planned manufacturing locations for KRTL in Bolivia?
How will KRTL's Bolivian expansion affect its U.S. market presence?
What research capabilities does the KRTL-CIQ partnership provide?
